ArticleBioorganic chemistry2020
Identification of new therapeutic targets and natural compounds against diffuse intrinsic pontine glioma (DIPG).
Article in Bioorganic chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Clinical outcomes of stereotactic biopsy on children with pontine diffuse midline glioma.Journal of neuro-oncology · 2023Trial
- Exploring epigenome-proteome interactions underlying post-surgical progression of non-functioning pituitary adenomas using hypernetwork modelling.Journal of translational medicine · 2026Article
- Microglia in diffuse midline glioma contribute to extracellular matrix remodelling and cancer cell invasion.Cell death & disease · 2026Article
- A perfused, parallelized blood brain barrier-tumor platform for compound permeation and efficacy investigations.Microsystems & nanoengineering · 2026Article
- Diffuse Midline Gliomas: Clinical, Diagnostic, and Therapeutic Perspectives.Biomedicines · 2026Review
- Inhibition of GPR68 induces ferroptosis in diffuse intrinsic pontine gliomas.Frontiers in oncology · 2026Article
- Expression and clinical value of EIF3CL in serous ovarian cancer.The Journal of international medical research · 2025Article
- Bulk and single-cell transcriptome revealed the metabolic heterogeneity in human glioma.Heliyon · 2025Article
- An uncommon presentation of early brainstem high-grade glioma in a 33-year-old male: A case study and review of literature.International journal of surgery case reports · 2024Article
- Identification of new microtubule small-molecule inhibitors and microtubule-associated genes against triple negative breast cancer.American journal of cancer research · 2024Article
- Pediatric oncology drug development and dosage optimization.Frontiers in oncology · 2023Review
- Frameless robot-assisted stereotactic biopsy: an effective and minimally invasive technique for pediatric diffuse intrinsic pontine gliomas.Journal of neuro-oncology · 2022Article
- dCas9 fusion to computer-designed PRC2 inhibitor reveals functional TATA box in distal promoter region.Cell reports · 2022Article
- Targeting Sphingosine Kinase by ABC294640 against Diffuse Intrinsic Pontine Glioma (DIPG).Journal of Cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Diffuse Intrinsic Pontine Glioma (DIPG) is a highly aggressive pediatric brainstem tumor which accounts for about 10-20% of childhood brain tumors. The survival rate for DIPG remains very poor, with a median survival of less than 1 year. The dismal prognosis associated with DIPG has been exacerbated by the failure of a large number of clinical trials to meaningfully improve survival compared with radiotherapy, the current standard of care for DIPG. In the current study, we screened a natural product library and for the first time identified 6 natural compounds displaying inhibitory effects on DIPG proliferation and anchorage-independent growth through inducing tumor cell apoptosis and cell cycle arrest. Subsequent RNA-Sequencing and functional validation revealed the molecular mechanisms of these compounds with anti-DIPG activities, and identified new cellular factors such as Fibronectin 1 (FN1) and Eukaryotic translation initiation factor 3 subunit C-like (EIF3CL), required for DIPG survival as potential therapeutic targets. Our study provides promising directions to fight against this deadly pediatric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.